Filing Details

Accession Number:
0001104659-24-007699
Form Type:
13G Filing
Publication Date:
2024-01-28 19:00:00
Filed By:
ARK Investment Management
Company:
Verve Therapeutics Inc.
Filing Date:
2024-01-29
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
ARK Investment Management 6,811,108 110,691 7,025,116 0 7,025,116 8.74%
Filing
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

SCHEDULE 13G

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

 

Verve Therapeutics, Inc.

 

(Name of Issuer)

 

Common stock 

 

(Title of Class of Securities)

 

92539P101

 

(CUSIP Number)

 

December 31, 2023 

 

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

x  Rule 13d-1(b) 

¨  Rule 13d-1(c) 

¨  Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

CUSIP No. 92539P101 13G Page 2 of 5 Pages 

 

1. NAMES OF REPORTING PERSONS    
ARK Investment Management LLC    
   
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP    
(a) ☐    
(b) ☐    
3. SEC USE ONLY    
     
   
4. CITIZENSHIP OR PLACE OF ORGANIZATION    
Delaware, United States    
   
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER    
 6,811,108    
   
6. SHARED VOTING POWER    
 110,691    
   
7. SOLE DISPOSITIVE POWER    
 7,025,116    
   
8. SHARED DISPOSITIVE POWER    
0    
   
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON    
  7,025,116    
   
10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES    
   
   
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)    
8.74%    
   
12. TYPE OF REPORTING PERSON    
IA    
   
           

 

 

 

 

CUSIP No. 92539P101 13G Page 3 of 5 Pages 

 

Item 1(a) Name of issuer:

 

Verve Therapeutics, Inc.

 

Item 1(b) Address of issuer's principal executive offices:

 

201 Brookline Avenue, Suite 601 

Boston, MA 02215

 

Item 2(a) Name of person filing:

 

ARK Investment Management LLC

 

Item 2(b) Address or principal business office or, if none, residence:

 

ARK Investment Management LLC 

200 Central Avenue 

St. Petersburg, FL 33701

 

Item 2(c) Citizenship:

 

Delaware, United States

 

Item 2(d) Title of class of securities:

 

Common stock

 

Item 2(e) CUSIP No.:

 

92539P101

 

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

 

(b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

 

(c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

 

(d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

 

(e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

 

(f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

 

(g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

 

(h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

(i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

(j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

 

(k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

 

 

 

 

CUSIP No. 92539P101 13G Page 4 of 5 Pages 

 

Item 4. Ownership

 

(a)          Amount beneficially owned:

 

7,025,116

 

(b)          Percent of class:

 

8.74%

 

(c)          Number of shares as to which such person has:

 

(i)  Sole power to vote or to direct the vote:  6,811,108

 

(ii) Shared power to vote or to direct the vote:  110,691

 

(iii) Sole power to dispose or to direct the disposition of:  7,025,116

 

(iv) Shared power to dispose or to direct the disposition of:  0

 

Item 5. Ownership of 5 Percent or Less of a Class.

 

Not applicable.

 

Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

 

To the knowledge of the Reporting Person, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, a number of the shares which represents more than five percent of the number of outstanding class of the shares.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9. Notice of Dissolution of Group.

 

Not applicable.

 

 

 

 

CUSIP No. 92539P101 13G Page 5 of 5 Pages 

 

Item 10. Certifications.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

The reporting persons agree that this statement is filed on behalf of each of them.

 

Dated:    January 29, 2024

 

  ARK Investment Management LLC  
     
  By: /s/ Kellen Carter
    Name: Kellen Carter
    Title: Chief Compliance Officer